Pfizer, 23andMe team up to study bowel disease

August 12, 2014

Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Under the partnership, 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn's disease and ulcerative colitis. Patients will submit saliva samples using 23andMe's at-home collection kit and then fill out online questionnaires about their disease and symptoms.

The companies say they hope to identify genetic similarities among patients with , which could guide development of targeted drugs to treat the disease.

The cause of is unknown, though many scientists suspect genetics play a role. Other scientists believe the diseases are triggered by a virus or bacteria.

Explore further: 23andMe faces class action lawsuit in California

Related Stories

Inflammatory bowel disease raises risk of melanoma

May 20, 2013

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...

Recommended for you

Rac1 protein critical for lung development

October 20, 2016

A study by researchers from The Saban Research Institute of Children's Hospital Los Angeles reveals a promising therapeutic target for improving lung function in infants. Their study, now published online by the American ...

A vitamin could help treat Duchenne muscular dystrophy

October 19, 2016

Duchenne is the most common and severe form of muscular dystrophy. Because of this genetic disease, one out of every 3,500 children spends their 12th birthday in a wheelchair. This disorder progressively leads to general ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.